Mirae Asset Mutual Fund
When comparing, both lines start at 100. The fund's declared benchmark, a total-return index (dividends reinvested).
Up to one year: absolute. Longer: annualised. Category = median of Equity ETF -plan Growth funds; index = NIFTY500 HEALTHCARE TRI.
| Period | This fund | Category median | NIFTY500 HEALTHCARE TRI | Rank in category |
|---|---|---|---|---|
| 1 month | -3.00% | -5.76% | -2.99% | — |
| 3 months | +1.07% | -4.47% | +1.12% | — |
| 6 months | +18.55% | +6.38% | +18.67% | — |
| 1 year | — | -2.47% | +13.61% | — |
| 3 years | — | +8.24% | +19.95% | — |
| 5 years | — | +8.53% | +13.21% | — |
| 10 years | — | — | +12.21% | — |
| Since launch of NAV data | — | — | — | — |
| Window | High | Low |
|---|---|---|
| 1 month | 22.0944 | 21.0713 |
| 3 months | 22.0944 | 20.8482 |
| 6 months | 22.0944 | 17.6266 |
| 1 year | — | — |
A period is a dash when the fund has not existed that long or its NAV history has a hole at the start date — never a partial figure.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | YTD | |
|---|---|---|---|---|---|---|---|
| This fund | — | — | — | — | — | — | — |
| Category median | +15.65% | +24.59% | +0.70% | +26.90% | +19.16% | +6.37% | -5.28% |
| NIFTY500 HEALTHCARE TRI | +63.63% | +19.04% | -13.57% | +38.27% | +41.42% | -2.03% | +12.79% |
The fund's declared benchmark, a total-return index (dividends reinvested).
Twenty checks of five points each: performance, portfolio, operations, and risk against reward. Only checks we have data for are counted.
Risk-free rate 6.06% (3-year annualised return of the NSE 1-day (overnight) rate index). Benchmark-relative ratios use NIFTY500 HEALTHCARE TRI. The fund's declared benchmark, a total-return index (dividends reinvested).
| Ratio | This fund | Category median | Against category |
|---|---|---|---|
| Sharpe ratio | — | 0.16 | — |
| Sortino ratio | — | 0.22 | — |
| Standard deviation | — | 16.03% | — |
| Maximum drawdown | — | -18.36% | — |
| Beta | — | 1.00 | — |
| R-squared | — | 100.0% | — |
| Jensen's alpha | — | -0.25% | — |
| Treynor ratio | — | 0.70 | — |
| Information ratio | — | -3.54 | — |
| Upside capture | — | 99.7% | — |
| Downside capture | — | 99.9% | — |
Computed from this fund's actual NAVs. A SIP buys at the first NAV of each month and is valued at the latest NAV. Past returns do not guarantee future ones.
Weights are % of the scheme's assets from the latest month-end disclosure available to Tradinity. The feed carries weights only: no quantities or rupee values.
Valuation ratios are weighted over the holdings we can match to a company (harmonic mean for P/E) and are withheld when they cover under half the portfolio.
| Holding | Sector | Weight | 3M change | P/E |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Healthcare | 9.90% | — | 143.5 |
| Divi's Laboratories Ltd. | Healthcare | 8.53% | — | 83.0 |
| Apollo Hospitals Enterprise Ltd. | Healthcare | 6.50% | — | 73.1 |
| Cipla Ltd. | Healthcare | 5.62% | — | 35.1 |
| Max Healthcare Institute Ltd. | Healthcare | 5.50% | — | 124.3 |
| Laurus Labs Ltd. | Healthcare | 5.28% | — | 122.0 |
| Torrent Pharmaceuticals Ltd. | Healthcare | 5.27% | — | 77.7 |
| Dr. Reddy's Laboratories Ltd. | Healthcare | 4.99% | — | 150.9 |
| Lupin Ltd. | Healthcare | 3.77% | — | 13.2 |
| Aurobindo Pharma Ltd. | Healthcare | 3.37% | — | 37.5 |
| Fortis Healthcare Ltd. | Healthcare | 3.35% | — | 255.5 |
| TREPS | — | 2.89% | — | — |
| Glenmark Pharmaceuticals Ltd. | Healthcare | 2.65% | — | 316.1 |
| Alkem Laboratories Ltd. | Healthcare | 2.21% | — | 29.1 |
| Biocon Ltd. | Healthcare | 2.08% | — | 596.5 |
| Zydus Lifesciences Ltd. | Healthcare | 2.06% | — | 32.6 |
| IPCA Laboratories Ltd. | Healthcare | 1.94% | — | 39.8 |
| Mankind Pharma Ltd. | Healthcare | 1.94% | — | 46.9 |
| Gland Pharma Ltd. | Healthcare | 1.63% | — | 34.4 |
| Aster DM Quality Care Ltd. | Healthcare | 1.43% | — | 205.8 |
| Sai Life Sciences Ltd. | Healthcare | 1.43% | — | 89.9 |
| Neuland Laboratories Ltd. | Healthcare | 1.40% | — | 56.5 |
| Krishna Institute of Medical Sciences Ltd. | Healthcare | 1.39% | — | 105.1 |
| Acutaas Chemicals Ltd. | Healthcare | 1.16% | — | 64.3 |
| Wockhardt Ltd. | Healthcare | 1.10% | — | 94.2 |
| Ajanta Pharma Ltd. | Healthcare | 1.08% | — | 43.2 |
| Dr. Lal Path labs Ltd. | Healthcare | 1.07% | — | 38.4 |
| Piramal Pharma Ltd. | Healthcare | 0.95% | — | 37.0 |
| Abbott India Ltd. | Healthcare | 0.94% | — | 34.5 |
| Narayana Hrudayalaya Ltd. | Healthcare | 0.93% | — | 61.9 |
| Global Health Ltd. | Healthcare | 0.90% | — | 74.4 |
| Glaxosmithkline Pharmaceuticals Ltd. | Healthcare | 0.89% | — | 43.8 |
| Granules India Ltd. | Healthcare | 0.85% | — | 49.5 |
| Onesource Specialty Pharma Ltd. | Healthcare | 0.85% | — | 358.6 |
| Anthem Biosciences Ltd. | Healthcare | 0.56% | — | 76.6 |
| Syngene International Ltd. | Healthcare | 0.54% | — | 62.8 |
| Natco Pharma Ltd. | Healthcare | 0.54% | — | 16.5 |
| Vijaya Diagnostic Centre Ltd. | Healthcare | 0.53% | — | 75.9 |
| Cohance Lifesciences Ltd. | Healthcare | 0.53% | — | 96.3 |
| Jubilant Pharmova Ltd. | Healthcare | 0.50% | — | 677.0 |
| Pfizer Ltd. | Healthcare | 0.50% | — | 23.9 |
| Rainbow Children's Medicare Ltd. | Healthcare | 0.50% | — | 51.3 |
| Eris Lifesciences Ltd. | Healthcare | 0.50% | — | 84.5 |
| Polymedicure Ltd. | Healthcare | 0.48% | — | 48.8 |
| Emcure Pharmaceuticals Ltd. | Healthcare | 0.45% | — | 45.3 |
| Indegene Ltd. | Healthcare | 0.45% | — | 63.4 |
| Caplin Point Laboratories Ltd. | Healthcare | 0.36% | — | 45.9 |
| Concord Biotech Ltd. | Healthcare | 0.34% | — | 50.3 |
| Blue Jet Healthcare Ltd. | Healthcare | 0.21% | — | 39.2 |
This is a paid feature
Comparing more months of this fund's own portfolio history is available on paid plans.
Sign inExpense ratio by month: Feb 26 0.11% · Mar 26 0.11% · Apr 26 0.14% · May 26 0.14% · Jun 26 0.43% · Jul 26 0.41% · Aug 26 0.35% · Sep 26 0.33%
NIL
The investment objective of the scheme is to generate returns, before expenses, that are commensurate with the performance of the Nifty 500 Healthcare Total Return Index, subject to tracking error.; There is no assurance that the investment objective of the scheme will be achieved.
Fund house: website · factsheets · monthly portfolio · annual report
Not available: Morningstar rating (proprietary). "NAV history from" is the first NAV we hold.
Returns are computed by Tradinity from each scheme's own published NAV, so they are net of the fund's expenses. Periods over one year are annualised (CAGR). Past performance does not indicate future returns. Only Growth-option schemes are ranked: an IDCW scheme pays cash out of its NAV, so its NAV understates what an investor earned.
